Clinical trials: Hormone Receptor-Positive Breast Cancer
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of tumor cells. Hormone therapy using therapeutic estradiol may fight breast cancer by lowering the amount of estrogen the body makes.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01385280
- Testing
- therapeutic estradiol, exemestane, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Arizona
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Breast Neoplasm
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.
- Trial name
- MEGA (NCT03024580)
- Testing
- Megestrol Acetate 160Mg Tablet, Anastrozole 1Mg Tablet, Letrozole 2.5Mg Tablet
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Breast Cancer
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00931450
- Testing
- exemestane, sunitinib malate
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Institut Català d'Oncologia
HR+/HER2- Early Breast Cancer
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE
The goal of this interventional study is to evaluate the effect of standardized patient coaching on treatment adherence among patients taking abemaciclib.
- Trial name
- IMPACT PT (NCT07521202)
- Testing
- Standardized patient coaching
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Institut fuer Frauengesundheit
Breast Cancer
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
This is a prospective, single arm phase II study to evaluate the efficacy and safety of fulvestrant as a maintenance hormone therapy after first-line chemotherapy for postmenopausal HR positive advanced breast cancer.
- Trial name
- FANCY (NCT02000193)
- Testing
- fulvestrant
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Invasive Early Breast Cancer
A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
The IES study (A5991012) investigated 4742 patients treated for 2 to 3 years with tamoxifen, who either continued the same treatment or switched to Aromasin® for a total treatment period of 5 years.
- Trial name
- NCT01121549
- Testing
- Aromasin
- Where
- 40 sites in Romania
- Volunteers
- 378 people
- Sponsor
- Pfizer
Breast Cancer
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.
- Trial name
- Ax-003 (NCT00638391)
- Testing
- Anastrozole
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Breast Cancer
Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
The purpose of this study is to assess Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Complete 5 Years of Toremifene
- Trial name
- LEXTOP (NCT01072318)
- Testing
- Letrozole
- Where
- South Korea
- Volunteers
- 495 people
- Sponsor
- Korean Breast Cancer Study Group
Breast Cancer
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer
The present study is a randomized open-label -phase III study that aims to compare the efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application of Zoladex up to 2-3 years for ≤ 45 year old…
- Trial name
- NCT01712893
- Testing
- Zoladex
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Fudan University
Breast Cancer
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive…
- Trial name
- FACT (NCT00256698)
- Testing
- Fulvestrant, Anastrozole
- Where
- 85 sites in Canada, Costa Rica and 10 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Breast Cancer
Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
The purpose of this study is to evaluate the use of an oral bisphosphonate (alendronate) in preventing bone loss in postmenopausal women with early breast cancer who are receiving anastrozole therapy, and to determine how long…
- Trial name
- BATMAN (NCT00122356)
- Testing
- Alendronate sodium
- Where
- 8 sites in Australia
- Volunteers
- 303 people
- Sponsor
- Barwon Health
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand
This study investigates the impact of breast cancer treatment on joint health, cartilage, composition, and bone structure in the knee and hand in patients with hormone-receptor positive stage I-III breast cancer and healthy…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04876378
- Testing
- Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to…
- Trial name
- NCT00291759
- Testing
- Tamoxifen, Anastrozole
- Where
- 52 sites in Austria
- Volunteers
- 3,858 people
- Sponsor
- AstraZeneca
Breast Cancer, Premenopausal Breast Cancer
Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer
Although combination endocrine therapy has been associated with significant reduction in risk of recurrence in younger women with hormone receptor positive breast cancer, it has been associated with more adverse effects and…
- Conditions
- Breast Cancer, Premenopausal Breast Cancer, Hormone Receptor Positive Tumor
- Trial name
- MyCHOICE (NCT03407768)
- Testing
- Individualized interventions
- Where
- 2 sites in Canada
- Volunteers
- 41 people
- Sponsor
- University of Saskatchewan
Breast Neoplasms
Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
This non-interventional study will be conducted in several Eastern European countries to assess the safety, tolerability and efficacy of Aromasin® when it is administered in real-word setting in postmenopausal women with invasive…
- Trial name
- NCT01239745
- Testing
- Aromasin
- Where
- 11 sites in Croatia, Estonia and 1 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Physical Activity
Exercise Training in Postmenopausal Patients With Breast Cancer
This randomized trial aims to assess if a well defined subgroup of breast cancer patients benefit from a controlled physical activity program.
- Trial name
- NCT01384838
- Testing
- Counseling, physical activity
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Metastatic Breast Cancer
Faslodex Registry: Fulvestrant in Current Clinical Practice
The sequential administration of endocrine therapies to patients with advanced breast cancer requires the availability of therapies with different modes of actions, so that tumours developing resistance to one agent are not cross…
- Trial name
- NCT00735215
- Where
- 12 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- AstraZeneca